U.S. Anti-obesity Prescription MarketsFrost & SullivanSeptember 26, 2006 115 Pages - SKU: MC1374680 |
|
Out-of-Pocket Healthcare 2012
4/3/2012 | published by: Kalorama Information
Despite numerous attempts to reign in costs of healthcare, consumers are increasingly paying for healthcare products and services from their own monies. The costs of health care products and services continue
|
more...
|
$995.00
|
|
World Market for Prescription Dermatological Drugs, 8th Edition (Antiacne, Antiaging, Dermatitis, Hair Loss, Psoriasis, Skin Cancer, Melasma and Seborrhea Treatments)
3/1/2012 | published by: Kalorama Information
This Kalorama Information report, The Worldwide Market for Prescription Dermatological Drugs represents the eighth time that Kalorama has detailed the various categories of prescription dermatological drugs, describing the global market and identifying major market factors
|
more...
|
$3,995.00
|
|
Chinese Markets for Hepatitis Drugs
4/1/2012 | published by: Asia Market Information & Development Company
China's demand for hepatitis drugs has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines China's economic
|
more...
|
$4,000.00
|
|
Spain Pharmaceuticals and Healthcare Report Q2 2012
3/20/2012 | published by: Business Monitor International
BMI View: Companies with significant exposure to debt-ridden European markets will be hard hit bygovernment austerity measures across the region, particularly by pharmaceutical price erosionmechanisms. The Spanish government’s austerity measures look set to continue to
|
more...
|
$1,175.00
|
|
West and Central Africa Pharmaceuticals and Healthcare Report Q2 2012
3/20/2012 | published by: Business Monitor International
BMI View: The better regulated markets of the Gulf Cooperation Council (GCC), South Africa and Israelwill remain the most rewarding and least risky for drugmakers operating in the Middle East and Africa(MEA). However, these markets
|
more...
|
$1,175.00
|
|
China Pharmaceutical Industry Research and Forecast to 2016
3/1/2012 | published by: AM Mindpower Solutions
EXECUTIVE SUMMARY The present report on “China Pharmaceutical Industry Research and Forecast to 2016” analyzes in detail the pharmaceutical industry environment with market sizing in terms of patented drugs, generic drugs, OTC drug and even sub-segments
|
more...
|
$700.00
|
|
Approval of Kalydeco Brings New Hope for CF Patients with G551D Mutation
2/29/2012 | published by: GlobalData
Approval of Kalydeco Brings New Hope for CF Patients with G551D Mutation Summary The report is an essential source of information and analysis on the KALYDECO (ivacaftor, VX-770) for the treatment of Cystic Fibrosis (CF) patients with
|
more...
|
$500.00
|
|
Brand Name Pharmaceutical Manufacturing in the US - Industry Market Research Report
3/21/2012 | published by: IBISWorld
Brand Name Pharmaceutical Manufacturing in the US Prescription for growth With healthcare reform allowing more individuals to gain prescription coverage, brand-name pharmaceutical and medicine manufacturers will experience a surge in demand. The expansion of biosimilar drugs will
|
more...
|
$910.00
|
|
The US Pharmaceutical Market Outlook to 2016 - Evolving Opportunities in the Biologics Segment
3/1/2012 | published by: AM Mindpower Solutions
EXECUTIVE SUMMARY The report titled “The US Pharmaceutical Market Outlook to 2015 – Evolving Opportunities in the Biologics Segment” provides a comprehensive analysis on the Pharmaceutical market in the US covering various aspects such as market
|
more...
|
$850.00
|
|
FDA Approves Erivedge (Vismodegib) for Metastatic or Locally Advanced Basal Cell Carcinoma
2/29/2012 | published by: GlobalData
FDA Approves Erivedge (Vismodegib) for Metastatic or Locally Advanced Basal Cell Carcinoma Summary GlobalData, the industry analysis specialist, has released its new report, “FDA Approves Erivedge (Vismodegib) for Metastatic or Locally Advanced Basal Cell Carcinoma”. The report
|
more...
|
$500.00
|
Related Markets
Prescription Drugs Reports
- Rx-to-OTC Switching Strategies - New Switching Opportunities in Weight Management and Smoking Cessation, but Encouraging the Uptake of Self-Medication Remains a Challenge
- Antivirals Market to 2017 - Increased Uptake of High Priced Combination Drugs will Offset the Impact of Generics in the HIV Therapeutics Market
- Pricing and Reimbursement in Russia - Big Pharma Take Advantage of Reimbursement for Costly Drugs Through the DLO’s Seven Nosologies Program
- Chinese Markets for Hepatitis Drugs
- Anti-Hypertensives Market to 2017 - Patent Expiries of Blockbusters such as Diovan, Micardis, Avapro and Atacand to Accelerate Erosion
